Democratizing RNA Innovation
Anticlastic Applications
UNIFIED DEVELOPMENT SOLUTION
Only Full-Stack ASO and siRNA Discovery & Development Solution Available to All Innovators
To advance the discovery and development of RNA-based medicines, Alloy Genetic Medicines provides the proprietary platforms, advanced technologies, and collaborative ecosystem needed to redefine therapeutic possibilities.
2-3x
10-40x
The AntiClastic™ Cyclic Oligonucleotide platform leverages proprietary cyclic architectures, including ASOs, siRNAs, and sgRNAs, to overcome the structural limitations of traditional linear oligonucleotide formats. This innovation unlocks diverse modalities for genetic medicines, including targeted RNA degradation, splice modulation, and gene editing.
Additionally, we are pairing Alloy Therapeutics’ well-known antibody discovery expertise with our genetic medicine capabilities to design and develop antibody-oligonucleotide conjugates (AOCs) that achieve exceptional cell- and organ-specific delivery.
Reshaping RNA Medicines
Cyclic Architectures Redefine Oligonucleotide Possibilities
Our AntiClastic Cyclic Oligonucleotide platform converts linear RNA medicines into IP-protected, configurable cyclic architectures that deliver nuclease-resistant therapeutics with greater potency, durability, specificity, and in vivo efficacy, while reducing immunostimulation. These structures extend beyond traditional chemical modification strategies, introducing architectural differentiation into RNA drug design.
AntiClastic Antisense Oligonucleotides: Superior Safety and Potency
AntiClastic ASOs outperform traditional gapmers, offering superior potency and safety. Validated across diverse mechanisms, this platform enables highly effective RNaseH-mediated decay of mRNA and regulatory RNAs, ADAR-mediated RNA editing, and precise splice modulation. By re-engineering spatial conformation, we deliver breakthrough genetic medicines that maximize therapeutic index.
AntiClastic siRNAs: Picomolar Potency with Durable Silencing
AntiClastic siRNAs leverage cyclic architecture and precision end-tuning to deliver picomolar RNAi potency with ASO-like versatility. Compared with conventional formats, inflammatory risks are reduced, and the platform achieves exceptional molecular stability, enabling 6–12-month dosing intervals rather than more frequent clinic visits.
AntiClastic sgRNA: Next-Generation Precision Editing
AntiClastic sgRNAs leverage a proprietary cyclic architecture to stabilize the guide RNA structure, thereby enhancing CRISPR-Cas9 precision. By shielding reactive ends, the platform increases nuclease resistance and significantly reduces off-target activity. This structural engineering optimizes on-target cleavage while minimizing immunogenicity, providing a safer, more potent engine for advanced genome editing.
Antibody Oligonucleotide Conjugates
Antibody Oligonucleotide Conjugates: Fusing Antibody Expertise with Genetic Innovation
By leveraging Alloy Therapeutics’ world-class antibody discovery engine, Alloy Genetic Medicines is pioneering advanced antibody-oligonucleotide conjugate (AOC) solutions. We identify and screen high-affinity antibody shuttles and targeting domains, enabling precise, cell- and organ-specific delivery. This synergy ensures payloads reach their targets with unmatched accuracy, maximizing therapeutic impact and patient outcomes.
Innovation Infrastructure
Unlocking the Potential of RNA Therapeutics with AntiClastic Innovation
Resources
Join Us in Shaping the RNA Century
Whether you are a global pharma leader, biotech, academic team, or other industry stakeholder, partner with Alloy Genetic Medicines to deliver next-generation genetic medicines to patients who need them.
